| Literature DB >> 32792015 |
Zhuo Liu1, Shiying Tang1, Xiaojun Tian1, Xun Zhao1, Peng Hong1, Qiming Zhang1, Liwei Li2, Li Zhang2, Shudong Zhang1, Guoliang Wang1, Hongxian Zhang1, Cheng Liu1, Guodong Zhu3, Lulin Ma4.
Abstract
BACKGROUND: We aimed to explore the causal analysis, clinical characteristics and treatment strategies of laparoscopic conversion to open approach (LCTOA) in radical nephrectomy and tumor thrombectomy.Entities:
Keywords: Conversion to open surgery; Laparoscopic approach; Renal cell carcinoma; Tumor thrombus
Mesh:
Year: 2020 PMID: 32792015 PMCID: PMC7430843 DOI: 10.1186/s12893-020-00845-1
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.102
Fig. 1A flowchart to visualize the patient selection process
Comparison of clinical and pathologic features between complete laparoscopic surgery group and laparoscopic converse to open surgery group
| Complete laparoscopic surgery group | Laparoscopic converse to open surgery group | ||
|---|---|---|---|
| mean value ± SD | |||
| Age, years | 61.0(51.0,68.0) | 61.0(54.0,68.0) | 0.995 |
| BMI, kg/m2 | 22.5(20.1,27.0) | 23.5(21.1,24.8) | 0.958 |
| Tumor diameter, cm | 8.3(5.4,10.3) | 9.1(7.1,11.0) | 0.214 |
| Albumin, g/L | 39.0(37.0,42.8) | 40.9(37.0,42.1) | 0.672 |
| Total Protein, g/L | 69.0(66.0,74.0) | 71.0(67.0,73.0) | 0.376 |
| Hemoglobin, g/L | 122.0(108.0,139.0) | 121.0(109.0,126.0) | 0.566 |
| Pre-operative serum creatinine, μmol/L | 92.0(80.0,111.0) | 110.0(89.0,130.0) | |
| Serum creatinine 1 week after operation, μmol/L | 103.0(86.0,117.0) | 112.0(79.0,122.0) | 0.658 |
| Hospital stay after operation, days | 7.0(5.0,10.0) | 9.0(8.0,12.0) | |
| Operative time,min | 311.0(219.0,464.0) | 374.0(343.0,495.0) | |
| Surgical bleeding volume,ml | 600.0(200.0,1500.0) | 1300.0(800.0,3000.0) | |
| Surgical blood transfusion volume,ml | 400.0(0.0,800.0) | 800.0(0.0,1600.0) | 0.087 |
| Plasma transfusion volume,ml | 0.0(0.0,200.0) | 0.0(0.0, 0.0) | 0.699 |
| N (%) | |||
| Sex | |||
| Male | 34(66.7%) | 18(94.7%) | |
| Female | 17(33.3%) | 1(5.3%) | |
| Side | 0.214 | ||
| Left | 16(31.4%) | 9(47.4%) | |
| Right | 35(68.0%) | 10(52.6%) | |
| American society of anesthesiologists score | 0.154 | ||
| 1 | 1(2.0%) | 2(10.5%) | |
| 2 | 44(86.3%) | 13(68.4%) | |
| 3 | 6(11.8%) | 4(21.1%) | |
| Clinical symptoms | 0.427 | ||
| No clinical symptoms | 14(27.5%) | 2(10.5%) | |
| Local symptoms | 25(49.0%) | 10(52.6%) | |
| Systemic symptoms | 6(11.8%) | 3(15.8%) | |
| Both | 6(11.8%) | 4(21.1%) | |
| cN stage | 0.975 | ||
| cN0 | 19(37.3%) | 7(36.8%) | |
| cN1 | 32(62.7%) | 12(63.2%) | |
| cM stage | 0.938 | ||
| cM0 | 29(56.9%) | 11(57.9%) | |
| cM1 | 22(43.1%) | 8(42.1%) | |
| Mayo classification | 0.146 | ||
| I | 26(51.0%) | 5(26.3%) | |
| II | 20(39.2%) | 10(52.6%) | |
| III | 5(9.8%) | 4(21.1%) | |
| IVC resection | 0.155 | ||
| No | 45(88.2%) | 14(73.7%) | |
| Yes | 6(11.8%) | 5(26.3%) | |
| Pathology type | 0.155 | ||
| Clear cell carcinoma | 45(88.2%) | 14(73.7%) | |
| Non clear cell carcinoma | 6(11.8%) | 5(26.3%) | |
| Nuclear classification | 0.856 | ||
| 2 | 16(31.4%) | 5(26.3%) | |
| 3 | 22(43.1%) | 8(42.1%) | |
| 4 | 13(25.5%) | 6(31.6%) | |
| Rhabdoid differentiation | 0.334 | ||
| No | 48(94.1%) | 16(84.2%) | |
| Yes | 3(5.9%) | 3(15.8%) | |
| Sarcomatoid differentiation | 1.000 | ||
| No | 46(90.2%) | 18(94.7%) | |
| Yes | 5(9.8%) | 1(5.3%) | |
| Invasion of perirenal fat | 0.260 | ||
| No | 37(72.5%) | 11(57.9%) | |
| Yes | 14(27.5%) | 8(42.1%) | |
| Postoperative complications | 0.902 | ||
| No | 26(51.0%) | 10(52.6%) | |
| Yes | 25(49.0%) | 9(47.4%) | |
Univariate analysis and multivariate analysis for laparoscopic surgery converted to open surgery
| Univariate logistic regression analysis | Multivariate logistic regression analysis | |||||
|---|---|---|---|---|---|---|
| OR | 95%CI | P | OR | 95%CI | P | |
| Mayo classification I | 0.161 | 0.406 | ||||
| Mayo classification II | 2.600 | 0.766–8.821 | 0.125 | 1.691 | 0.421–6.799 | 0.459 |
| Mayo classification III | 4.160 | 0.818–21.153 | 0.086 | 3.864 | 0.531–28.100 | 0.182 |
| cN stage | 1.018 | 0.342–3.032 | 0.975 | 0.791 | 0.226–2.770 | 0.714 |
| Pre-operative serum creatinine | 1.027 | 1.001–1.054 | 0.039 | 1.014 | 0.987–1.042 | 0.316 |
| Gender | 0.111 | 0.014–0.904 | 0.040 | 0.168 | 0.017–1.630 | 0.124 |
| IVC resection | 2.679 | 0.709–10.125 | 0.146 | 2.033 | 0.440–9.391 | 0.364 |
| Tumor diameter > 10 cm | 1.400 | 0.461–4.247 | 0.552 | 1.228 | 0.329–4.579 | 0.760 |
Fig. 2All risk factors of laparoscope conversion to open approach in radical nephrectomy and tumor thrombectomy
Fig. 3Laparoscope conversion to open approach in renal treatment part and tumor thrombus treatment part. In renal treatment part: 1) From A to B: The kidney was dissociated along the perirenal fascia; 2) From B to C: To separate the anatomical layers between the renal tumor and the surrounding tissues and organs; 3) From C to D: circulatory instability caused by hemorrhage; 4) From D to E: active conversion to open surgery. In tumor thrombus treatment part: 1) From E to F: To separate the anatomical layers between IVC and surrounding tissues and organs; 2) From F to G: The IVC tumor thrombus was removed; 3) From G to H: The walls of IVC were sutured
Fig. 4Cancer-specific survival time between laparoscope conversion to open approach (LCTOA) group and complete laparoscopic approach group